Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis (NCT07284459)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Who can join: Review the eligibility criteria below.
Location: Instituto Ave Pulmo — Mar del Plata, Buenos Aires
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (69 Sites)
Showing the first 25 of 69 sites.
- Instituto Ave Pulmo — Mar del Plata, Buenos Aires
- Centro Respiratorio Quilmes — Quilmes, Buenos Aires
- Instituto de Especialidades de la Salud Rosario - Clínica del Tórax — Rosario, Santa Fe Province
- Instituto Médico de la Fundación Estudios Clínicos — Rosario, Santa Fe Province
- Centro de Diagnóstico Y Rehabilitación - Santa Fe - San Luis — San Luis, Santa Fe Province
- Centro de Investigaciones Médicas Tucumán - PPDS — San Miguel de Tucumán, Tucumán Province
- CIMER-Centro Integral de Medicina Respiratoria — San Miguel de Tucumán, Tucumán Province
- IPR-Investigaciones en Patologías Respiratorias — San Miguel de Tucumán, Tucumán Province
- Centro Modelo de Cardiología-Laprida 554 — San Miguel de Tucumán, Tucumán Province
- STAT Research S.A. — Buenos Aires,
- Consultorios Médicos Organización del Buen Ayre SRL — Buenos Aires,
- Centro Médico Dra de Salvo - Fundacion Respirar - PPDS — Buenos Aires,
- Instituto de Medicina Respiratoria - IMER — Córdoba,
- IbaMedica — Santa Fe,
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Westmead Hospital — Westmead, New South Wales
- The Prince Charles Hospital — Chermside, Queensland
- Greenslopes Private Hospital — Greenslopes, Queensland
- Austin Health — Heidelberg, Victoria
- The Alfred Hospital — Melbourne, Victoria
- Institute for Respiratory Health — Midland, Western Australia
- TrialsWest Pty Ltd — Spearwood, Western Australia
- Vancouver General Hospital — Vancouver, British Columbia
- Toronto General Hospital — Toronto, Ontaria
- Dynamic Drug Advancement Ltd. — Ajax, Ontario
📞 Contact the Study Coordinator
Phone: (858) 333-5280
Email: nnepomuceno@contineum-tx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.